Study of Oral MRT-2359 in Selected Cancer Patients (NCT05546268)
A Phase 1/2 Study of Oral MRT-2359 in Patients With MYC-Driven and Other Selected Solid Tumors Including Lung Cancer and Diffuse B-Cell Lymphoma
🩺 Plain-English Summary (8th-Grade Level)
This Phase 1/2, open-label, multicenter study is conducted in patients with previously treated selected solid tumors, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), high-grade neuroendocrine cancer of any primary site, diffuse large B-cell lymphoma (DLBCL), and tumors with L-MYC or N-MYC amplification. Patients receive escalating doses of a GSPT1 molecular glue degrader MRT-2359 to determine safety, tolerability, maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of MRT-2359. Once the MTD and/or RP2D is identified, additional patients enroll to Phase 2 study, which includes molecular biomarkers stratification or selection, namely expression or amplification of L-MYC and N-MYC genes, hormone receptor positive (HR)-positive, human epidermal growth factor 2 (HER2)-negative breast cancer and prostate cancer.
Who can join: Review the eligibility criteria below.
Location: Honor Health Research Institute — Scottsdale, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (17 Sites)
- Honor Health Research Institute — Scottsdale, Arizona
- University of California San Diego — San Diego, California
- Yale University — New Haven, Connecticut
- University of Kansas Cancer Center — Lawrence, Kansas
- Dana Farber Cancer Institute — Boston, Massachusetts
- Henry Ford Cancer Institute — Detroit, Michigan
- South Texas Accelerated Research Therapeutics (START) Midwest — Grand Rapids, Michigan
- Washington University — St Louis, Missouri
- Memorial Sloan Kettering Cancer Center — New York, New York
- Columbia University Irving Medical Centre — New York, New York
- Sarah Cannon Research Institute — Nashville, Tennessee
- Mary Crowley Cancer Research — Dallas, Texas
- MD Anderson Cancer Center — Houston, Texas
- South Texas Accelerated Research Therapeutics (START) — San Antonio, Texas
- South Texas Accelerated Research Therapeutics (START) Mountain Region — West Valley City, Utah
- Virginia Cancer Specialists Research Institute — Fairfax, Virginia
- Fred Hutchinson Cancer Center — Seattle, Washington
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in NSCLC
- Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy — Savannah, Georgia
- A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC — Daphne, Alabama
- LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic Patients — Chicago, Illinois
- Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC — La Jolla, California
- A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care — Boston, Massachusetts
Explore by condition: All NSCLC clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.